PD-1 dominant negative TurboCAR T cells (Allogene Therapeutics)

N/A

Report date: 2025/01/26 19:22:29

Base Information

Drug NamePD-1 dominant negative TurboCAR T cells (Allogene Therapeutics)

Drug Alias NameCAR T-cell therapy expressing a dual PD-L1 checkpoint inhibitor/PD-L2 checkpoint inhibitor (Allogene Therapeutics)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionProgrammed death-ligand 1 blockersProgrammed death-ligand 2 inhibitors

TargetsProgrammed death-ligand 2Programmed death-ligand 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAllogene Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAllogene Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A